Showcasing SOL-257, a Chaperone-based Gene Therapy Targeting Misfolded TDP-43 in ALS

Time: 11:30 am
day: Day Two Track A AM


  • Highlighting in vivo proof-of-concept data demonstrating successful re-folding or degradation of misfolded TDP-43
  • Outlining corroborating iPSC-derived evidence
  • Demonstrating translational potential of SOL-257 gene therapy to treat TDP-43 dysfunction in ALS patients